Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report

Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report

Introduction: Durvalumab 10 mg/kg every 2 weeks for 1 year after chemoradiation has improved overall survival (OS) in unresectable stage III NSCLC. Subsequently, a 20 mg/kg 4-weekly regimen was approved. The study goal was to compare the efficacy and toxicity of the two regimens. Methods: All patien...

Full description

Bibliographic Details
Main Authors: Marie-Hélène Denault, MD, MSc, Shelley Kuang, MD, FRCPC, Aria Shokoohi, BSc, Bonnie Leung, MN-NP, Mitchell Liu, MDCM, FRCPC, Eric Berthelet, MD, FRCPC, Janessa Laskin, MD, FRCPC, Sophie Sun, MD, FRCPC, Tina Zhang, MD, FRCPC, Barbara Melosky, MD, FRCPC, Cheryl Ho, MD, FRCPC
Format: Article
Language:English
Published: Elsevier 2022-05-01
Series:JTO Clinical and Research Reports
Subjects:
Advanced non–small cell lung cancer
Durvalumab
Adjuvant
Immune checkpoint inhibitors
Immune-related toxicity
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322000406

Similar Items

Similar Items